IKB Deutsche Industriebank
IKB Deutsche Industriebank AG is a commercial bank based in Düsseldorf, Germany, established in 1924. It specializes in providing financial services to medium-sized enterprises and private equity funds across Germany and Europe. The bank offers a wide range of services, including loans, risk management, capital market products, and advisory services. Its expertise encompasses acquisition financing, syndicate financing, export and project financing, as well as equity and debt capital market transactions. IKB is committed to maintaining long-term relationships with its clients, which include companies in various sectors such as healthcare, logistics, energy, real estate, and technology. With around 1,450 employees, IKB operates in several major cities, including Berlin, Frankfurt, and Munich, and has a strong understanding of the unique challenges faced by medium-sized enterprises.
3 past transactions
Cardion
Venture Round in 2002
Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen.
Ingenium Pharmaceuticals AG
Series B in 2000
Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.
EpiCept
Series B in 2000
EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.